Atypical fibroxanthoma and pleomorphic dermal sarcoma

Atypical fibroxanthoma and pleomorphic dermal sarcoma: Local recurrence and metastasis in a nationwide population-based cohort of 1118 patients

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Atypical fibroxanthoma and pleomorphic dermal sarcoma : Local recurrence and metastasis in a nationwide population-based cohort of 1118 patients. / Ørholt, Mathias; Abebe, Kiya; Rasmussen, Louise E.; Aaberg, Frederik L.; Lindskov, Lærke J.; Schmidt, Grethe; Wagenblast, Anne Lene; Petersen, Michael M.; Loya, Anand C.; Daugaard, Søren; Herly, Mikkel; Jensen, David Hebbelstrup; Vester-Glowinski, Peter.

In: Journal of the American Academy of Dermatology, Vol. 89, No. 6, 2023, p. 1177-1184.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Ørholt, M, Abebe, K, Rasmussen, LE, Aaberg, FL, Lindskov, LJ, Schmidt, G, Wagenblast, AL, Petersen, MM, Loya, AC, Daugaard, S, Herly, M, Jensen, DH & Vester-Glowinski, P 2023, 'Atypical fibroxanthoma and pleomorphic dermal sarcoma: Local recurrence and metastasis in a nationwide population-based cohort of 1118 patients', Journal of the American Academy of Dermatology, vol. 89, no. 6, pp. 1177-1184. https://doi.org/10.1016/j.jaad.2023.08.050

APA

Ørholt, M., Abebe, K., Rasmussen, L. E., Aaberg, F. L., Lindskov, L. J., Schmidt, G., Wagenblast, A. L., Petersen, M. M., Loya, A. C., Daugaard, S., Herly, M., Jensen, D. H., & Vester-Glowinski, P. (2023). Atypical fibroxanthoma and pleomorphic dermal sarcoma: Local recurrence and metastasis in a nationwide population-based cohort of 1118 patients. Journal of the American Academy of Dermatology, 89(6), 1177-1184. https://doi.org/10.1016/j.jaad.2023.08.050

Vancouver

Ørholt M, Abebe K, Rasmussen LE, Aaberg FL, Lindskov LJ, Schmidt G et al. Atypical fibroxanthoma and pleomorphic dermal sarcoma: Local recurrence and metastasis in a nationwide population-based cohort of 1118 patients. Journal of the American Academy of Dermatology. 2023;89(6):1177-1184. https://doi.org/10.1016/j.jaad.2023.08.050

Author

Ørholt, Mathias ; Abebe, Kiya ; Rasmussen, Louise E. ; Aaberg, Frederik L. ; Lindskov, Lærke J. ; Schmidt, Grethe ; Wagenblast, Anne Lene ; Petersen, Michael M. ; Loya, Anand C. ; Daugaard, Søren ; Herly, Mikkel ; Jensen, David Hebbelstrup ; Vester-Glowinski, Peter. / Atypical fibroxanthoma and pleomorphic dermal sarcoma : Local recurrence and metastasis in a nationwide population-based cohort of 1118 patients. In: Journal of the American Academy of Dermatology. 2023 ; Vol. 89, No. 6. pp. 1177-1184.

Bibtex

@article{9833f92af512421cac6df4a9ced4284d,

title = "Atypical fibroxanthoma and pleomorphic dermal sarcoma: Local recurrence and metastasis in a nationwide population-based cohort of 1118 patients",

abstract = "Background: The prognosis of patients with atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) remains uncertain and no standardized follow-up programs have been established. Objective: To recommend a standardized follow-up program of patients with AFX and PDS based on nationwide long-term estimates of local recurrence and metastasis. Methods: All patients with AFX and PDS in Denmark between 2002 and 2022 were included. Danish National Registries were used to estimate the risks of local recurrence and metastasis for AFX and PDS. Results: The 5-year risk of local recurrence was 10% for AFX and 17% for PDS. The 5-year risk of metastasis was 0.8% for AFX and 16% for PDS. PDS metastasized within 3 years in >90% of the patients with the lungs as the primary metastasis site (50%). Invasion beyond the subcutis, perineural/intravascular infiltration, and increasing age significantly increased the risk of PDS relapse. Limitations: Risk of misclassification and lack of detailed surgical information. Conclusion: The follow-up of patients with AFX can be limited to clinical visits for 4 years. Patients with PDS should be followed with clinical visits and PET/CT twice a year for the first 3 years and once a year for a minimum of 1 year.",

keywords = "atypical fibroxanthoma, local recurrence, metastasis, pleomorphic dermal sarcoma, prognosis, relapse, risk factors",

author = "Mathias {\O}rholt and Kiya Abebe and Rasmussen, {Louise E.} and Aaberg, {Frederik L.} and Lindskov, {L{\ae}rke J.} and Grethe Schmidt and Wagenblast, {Anne Lene} and Petersen, {Michael M.} and Loya, {Anand C.} and S{\o}ren Daugaard and Mikkel Herly and Jensen, {David Hebbelstrup} and Peter Vester-Glowinski",

note = "Publisher Copyright: {\textcopyright} 2023 American Academy of Dermatology, Inc.",

year = "2023",

doi = "10.1016/j.jaad.2023.08.050",

language = "English",

volume = "89",

pages = "1177--1184",

journal = "American Academy of Dermatology. Journal",

issn = "0190-9622",

publisher = "Mosby Inc.",

number = "6",

}

RIS

TY - JOUR

T1 - Atypical fibroxanthoma and pleomorphic dermal sarcoma

T2 - Local recurrence and metastasis in a nationwide population-based cohort of 1118 patients

AU - Ørholt, Mathias

AU - Abebe, Kiya

AU - Rasmussen, Louise E.

AU - Aaberg, Frederik L.

AU - Lindskov, Lærke J.

AU - Schmidt, Grethe

AU - Wagenblast, Anne Lene

AU - Petersen, Michael M.

AU - Loya, Anand C.

AU - Daugaard, Søren

AU - Herly, Mikkel

AU - Jensen, David Hebbelstrup

AU - Vester-Glowinski, Peter

PY - 2023

Y1 - 2023

N2 - Background: The prognosis of patients with atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) remains uncertain and no standardized follow-up programs have been established. Objective: To recommend a standardized follow-up program of patients with AFX and PDS based on nationwide long-term estimates of local recurrence and metastasis. Methods: All patients with AFX and PDS in Denmark between 2002 and 2022 were included. Danish National Registries were used to estimate the risks of local recurrence and metastasis for AFX and PDS. Results: The 5-year risk of local recurrence was 10% for AFX and 17% for PDS. The 5-year risk of metastasis was 0.8% for AFX and 16% for PDS. PDS metastasized within 3 years in >90% of the patients with the lungs as the primary metastasis site (50%). Invasion beyond the subcutis, perineural/intravascular infiltration, and increasing age significantly increased the risk of PDS relapse. Limitations: Risk of misclassification and lack of detailed surgical information. Conclusion: The follow-up of patients with AFX can be limited to clinical visits for 4 years. Patients with PDS should be followed with clinical visits and PET/CT twice a year for the first 3 years and once a year for a minimum of 1 year.

AB - Background: The prognosis of patients with atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) remains uncertain and no standardized follow-up programs have been established. Objective: To recommend a standardized follow-up program of patients with AFX and PDS based on nationwide long-term estimates of local recurrence and metastasis. Methods: All patients with AFX and PDS in Denmark between 2002 and 2022 were included. Danish National Registries were used to estimate the risks of local recurrence and metastasis for AFX and PDS. Results: The 5-year risk of local recurrence was 10% for AFX and 17% for PDS. The 5-year risk of metastasis was 0.8% for AFX and 16% for PDS. PDS metastasized within 3 years in >90% of the patients with the lungs as the primary metastasis site (50%). Invasion beyond the subcutis, perineural/intravascular infiltration, and increasing age significantly increased the risk of PDS relapse. Limitations: Risk of misclassification and lack of detailed surgical information. Conclusion: The follow-up of patients with AFX can be limited to clinical visits for 4 years. Patients with PDS should be followed with clinical visits and PET/CT twice a year for the first 3 years and once a year for a minimum of 1 year.

KW - atypical fibroxanthoma

KW - local recurrence

KW - metastasis

KW - pleomorphic dermal sarcoma

KW - prognosis

KW - relapse

KW - risk factors

U2 - 10.1016/j.jaad.2023.08.050

DO - 10.1016/j.jaad.2023.08.050

M3 - Journal article

C2 - 37634740

AN - SCOPUS:85171275135

VL - 89

SP - 1177

EP - 1184

JO - American Academy of Dermatology. Journal

JF - American Academy of Dermatology. Journal

SN - 0190-9622

IS - 6

ER -

ID: 369357725